Veracyte | VCYT - Operating Expenses


Veracyte reported $116M in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
Agenus USD 19.81M 293.94M Dec/2025
Agilent USD 1.44B 27M Dec/2025
Anika Therapeutics USD 29.97M 116.84M Dec/2025
Arrowhead Research USD 223.22M 10.86M Dec/2025
Bruker USD 900.9M 124.3M Dec/2025
Heron Therapeutics USD 40.55M 1.46M Dec/2025
Illumina USD 903M 69M Dec/2025
Intrexon USD 61.56M 26.1M Jun/2024
Karyopharm Therapeutics USD 51.92M 9.9M Dec/2025
Laboratory Of America USD 3.13B 32.4M Dec/2025
Ligand Pharmaceuticals USD 8.29M 32.17M Sep/2025
Myriad Genetics USD 212.8M 16.2M Dec/2025
Rigel Pharmaceuticals USD 117.61M 35.67M Sep/2025
Roche Holding CHF 21.01B 10.84B Dec/2025
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Siemens EUR 16.57B 2.29B Dec/2025
Sonic Healthcare AUD 4.23B 2.14B Dec/2024
Thermo Fisher Scientific USD 9.09B 821M Mar/2026
Veracyte USD 116M 7.24M Dec/2025
Waters USD 661.85M 1.67B Dec/2025